OncLive SOSS

Authors

Gyorgy Petrovics, PhD

Latest:

Gyorgy Petrovics on Frequency of BRCA Mutations in African American Prostate Cancer Patients

Gyorgy Petrovics, PhD, associate director, Center for Prostate Disease Research (CPDR), research associate professor in the department of surgery at the Uniformed Services University of the Health Sciences (USUHS), discusses BRCA1 and BRCA2 mutations in African American prostate cancer patients.

Gypsyamber DSouza, PhD

Latest:

Dr. D'Souza on Screening for HPV-Related Cancers

Gypsyamber D'Souza, PhD, MPH, MS, an associate professor of epidemiology at Johns Hopkins University, comments on screening for HPV-related cancers.

H. Jack West, MD

Latest:

Final Thoughts on Effective Therapy and Financial Toxicity

Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.

H. Jack West, MD, Swedish Cancer Institute

H. Omer Ikizler, MD

Latest:

PrimeMD, a Pain Reporting Smartphone Application for Patients Undergoing Head and Neck Radiation

A feasibility study of a smartphone application that patients undergoing radiation therapy for head and neck cancer can use to regularly report mucositis symptoms.

Habte A. Yimer, MD

Latest:

Dr. Yimer on Long-Term Proteasome Inhibition in Newly Diagnosed Myeloma

Habte A. Yimer, MD, of Texas Oncology, discusses a real-world study evaluating the long-term use of proteasome inhibition in patients with multiple myeloma, and transitioning from bortezomib (Velcade) to ixazomib (Ninlaro).

Haejin In, MD, MPH, MBA, FACS

Latest:

Dr In on the Importance of Early Cancer Prevention Strategies in Gastric Cancer

Haejin In, MD, MPH, MBA, FACS, FSSO, discusses the importance of identifying individuals at high risk for developing gastric cancer.

Hagen F. Kennecke, MD, MHA, FRCPC

Latest:

Dr. Kennecke on Available Treatments for GEP-NETs

Hagen F. Kennecke, MD, MHA, FRCPC, discusses the treatments available for patients with advanced gastroenteropancreatic neuroendocrine tumors.

Hagop M. Kantarjian, MD

Latest:

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Dr. Hagop Kantarjian presents the Phase I/II SAVE trial results, showcasing the promising efficacy and safety of the all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax in relapsed/refractory AML, achieving high response rates and MRD negativity in heavily pretreated patients.

Haiying Cheng, MD

Latest:

Dr. Cheng Discusses RICTOR Amplification in Lung Cancer

Haiying Cheng, MD, medical oncologist, Montefiore Einstein Center for Cancer Care, assistant professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discuses RICTOR amplification in patients with lung cancer.

Latest:

Dr. Choy Discusses Therapy for Oligometastatic Lung Cancer

Hak Choy, MD, Nancy B. & Jake L. Hamon Distinguished Chair in Therapeutic Oncology Research, Department of Radiation Oncology, UT Southwestern Medical Center, discuses therapy for patients with oligometastatic lung cancer.

Halle Moore, MD

Latest:

Dr. Moore on the Use of Preventive Anastrozole Versus Tamoxifen in DCIS

Halle Moore, MD, discusses the use of preventive anastrozole versus tamoxifen in ductal carcinoma in situ.

Hanmath J Neboori, MD

Latest:

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Hannah Kent-Ritchie, PhD

Latest:

Experts Give Advice on How to Plan a Successful Lung Cancer Screening Program

Screening high-risk individuals for lung cancer with low-dose tomography is an effective and recommended approach for reducing mortality from the condition. That said, planning a lung cancer screening program can be challenging, as a successful program requires strategic multidisciplinary.

Latest:

Paving the Way to Modern Cancer Therapy

When George P. Canellos, MD, first joined the field of oncology in the 1960s, many of his peers thought he was making huge mistake.

Hanneke Poort, PhD

Latest:

Addressing Fatigue as an Adverse Event in Ovarian and Uterine Cancers

Hanneke Poort, PhD, discusses research regarding fatigue as an adverse event in patients with gynecologic cancer.

Hans-Christian Kolberg, MD

Latest:

Dr. Kolberg on Collecting Real-World Biosimilar Trastuzumab Data in Breast Cancer

Hans-Christian Kolberg, MD, discusses collecting real-world data for biosimilars, specifically the trastuzumab biosimilar ABP 980 for breast cancer.

Hans Hammers, MD, PhD

Hans Hammers, MD, PhD, is a professor in the Department of Internal Medicine, a member of the Division of Hematology and Oncology, coleader of Clinical Research and Immunotherapy for the Kidney Cancer Research Program, and the Eugene P. Frenkel, MD Scholar in Clinical Medicine at the University of Texas Southwestern Medical Center

Latest:

Dr Hammers on Considerations for Assessing TKI/Immunotherapy Response in ccRCC

Hans Hammers, MD, PhD, discusses factors that may influence depth of response to IO/TKI or IO/IO therapy in advanced clear cell renal cell carcinoma.

Hans J. Hammers, MD, PhD, UT Southwestern Medical Center

Latest:

Scenario 3: A 44-Year-Old Woman With RCC at Intermediate-High Risk for Recurrence

Expert panelists highlight aspects of a final patient scenario, discussing adjuvant treatment strategies in the setting of renal cell carcinoma at intermediate-high risk for recurrence.

Hans-Joachim Schmoll, MD

Latest:

Dr. Schmoll on the Toxicity of the CHARTA Study in CRC

Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).